MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
MindMed works to improve patient outcomes through our pipeline of novel drug candidates and digital therapeutics.
We strive to deliver on the therapeutic potential of psychedelics and other novel compounds to address unmet patient needs in the fields of psychiatry, addiction, pain and neurology.
Anxiety
21%
1-year prevalence of anxiety disorders in the US
ADHD
4.4%
Estimated prevalence among US adults
Autism Spectrum Disorder
$461B
Economic cost of ASD in the US predicted by 2025
A Global Leader in Brain Health
MindMed uses industry-leading drug development expertise in its mission to unlock the full therapeutic potential of psychedelics and other novel therapeutic targets.
Research & Development Pipeline
Our pipeline offers opportunities across diverse therapeutic areas and mechanisms of action
Explore MindMed’s R&D Programs to learn more about the opportunities that exist to advance novel treatments for a wide range of brain health disorders.
We have the right people working for the right reasons.
Our world-class team of drug developers and digital medicine experts was built to advance innovative solutions for the major unmet medical need in brain health disorders.
Robert Barrow
Chief Executive Officer and Board Director
Schond Greenway, MBA
Chief Financial Officer
Miri Halperin Wernli, PhD
Executive President
Daniel Karlin, MD, MA
Chief Medical Officer
Mark Sullivan, JD
Chief Legal Officer and Corporate Secretary
Francois Lilienthal, MD, MBA
Chief Commercial Officer
Carrie Liao, CPA
Chief Accounting Officer
Robert Silva, PhD
VP, Head of Development
Bridget Walton, MS
VP, Global Regulatory Affairs
Maxim Jacobs, CFA
VP, Investor Relations and Corporate Communications
Carole Abel, MBA
VP, Programs and Portfolio Office (PPO)
Peter Mack, PhD
VP, Pharmaceutical Development
Corklin Steinhart, MD, PhD
VP, Global Medical Affairs
Phong Duong, PharmD
VP, Global Market Access